OncoMatch/Clinical Trials/NCT03683433
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Is NCT03683433 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Azacitidine and Enasidenib Mesylate for acute bilineal leukemia.
Treatment: Azacitidine · Enasidenib Mesylate — This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: IDH2 mutation
Disease stage
Required: Stage REFRACTORY, NEWLY DIAGNOSED (ELDERLY, NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY)
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Kidney function
creatinine < 2 unless related to the disease
Liver function
total bilirubin < 2 x uln unless increase is due to gilbert's disease or leukemic involvement; ast and/or alt < 3 x uln unless considered due to leukemic involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify